인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록·키워드
Abstract Background Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy that gradually damages joints. The pathogenesis of PsA involves immune-mediated chronic inflammation, resulting in tissue damage. Calprotectin (S100A8/A9) (CLP) acts as a proinflammatory factor of innate immunity, thus contributing to chronic inflammatory conditions. Aim of the work To evaluate whether serum CLP could reflect disease activity and pathological findings detected by musculoskeletal ultrasound in PsA patients receiving biological therapy. Patients and methods There were 120 participants in this cohort study: 60 patients with PsA receiving biological therapy for more than three months and 60 healthy controls. The Disease Activity in Psoriatic Arthritis (DAPSA) and the Psoriasis Area and Severity Index (PASI) were used to assess patients with PsA. A human CLP ELISA kit was used to measure serum CLP. Musculoskeletal ultrasound was performed on the dominant site using the PsASon13 composite score to evaluate inflammatory and structural changes. Results The median age of PsA patients was 35 years, and 68.3% of them were female. The PsASon13 imaging score had a median (IQR) of 7.0 (3.0–14.0). Median serum CLP levels were significantly higher in patients compared to controls (1468.4 vs. 1169.7 ng/mL, p < 0.001). ESR levels also revealed a significant difference among groups ( p = 0.005). DAPSA and PsASon13 scores showed a strong positive correlation, and both were significantly correlated with serum CLP ( p < 0.001). PASI score was correlated with DAPSA (rho = 0.494) and SON13 (rho = 0.435) scores ( p < 0.001). ROC curve analysis of serum CLP showed 73.3% sensitivity and 81.7% specificity in differentiating PsA patients from controls at an optimal cut-off value of 1285 ng/mL. Conclusions Serum CLP is a promising biomarker for monitoring disease activity in PsA, reflecting both clinical and ultrasound-assessed inflammation, and may aid management of patients on biologic therapy.
인공지능 문자 인식 모델을 통해 추출된 텍스트로, 일부 오타나 오류가 포함될 수 있으나 지속적으로 개선 중입니다.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
최근 본 자료 전체보기
